Company / Accounts Receivable
Dianthus Therapeutics, Inc. /DE/ Accounts Receivable History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$52.0K
FY2025
5-year range
$52.0K / $4.7M
FY2022-FY2025
Trend
-93.6%
vs FY2024
Sector context
#114 of 115
Health Care
What the data says
Among 115 Health Care companies, Dianthus Therapeutics, Inc. /DE/ is in the bottom 1% for accounts receivable. Declined from $294,000 to $52,000 over the past 2 years.
Based on SEC 10-K filings.
$52,000 in FY2025 with a 3-year CAGR of -77.7%.
Declined from $294,000 to $52,000 over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -77.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 115This company $52.0K Sector average $1.1B
▼
-100.0% below sector average
Key checks
Key Insights
- 3-year CAGR of -77.7%, indicating a declining trend.
- In FY2025, accounts receivable decreased 93.6% year-over-year.
- Ranks #114 out of 115 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $52.0K | -93.6% |
| FY2024 | $807.0K | +174.5% |
| FY2023 | $294.0K | -93.7% |
| FY2022 | $4.7M | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026